Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 10th January 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

PetMedix and Zoetis to collaborate on antibody therapies
"Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets" - Robert J. Polzer, Zoetis.

Firms will use transgenic platforms for antibody discovery.

PetMedix has joined forces with Zoetis to develop new species-specific
animal monoclonal antibody therapies (mAbs) using its proprietary transgenic platforms.

Through the partnership, PetMedix will carry out discovery activities against a number of key targets, while Zoetis will have exclusive rights to develop and bring these therapies to market.

Having already brought three novel mAbs to market, Zoetis is a leader in companion animal antibody therapeutics, including fully species-specific antibodies.

PetMedix chief executive Dr Tom Weaver commented: "We are excited to be partnering with Zoetis. Bringing together our unique pet antibody discovery engine with their proven ability to not just develop antibodies, but also make them a commercial success, is set to be a winning combination."

While many technologies have been used to develop human therapeutic antibodies, 40 years of research highlights the benefits of antibodies which are 100 per cent species-matched to the patient.

PetMedix is looking to build on this success for companion animals. Its Ky9™ and Felyne™ platforms were developed in the same way as the leading human transgenic platforms. The collaboration also marks the third publicly-announced deal Zoetis has made with companies using transgenic platforms for antibody discovery.

Zoetis executive vice president and president Robert J. Polzer, said: "At Zoetis, we are committed to continuing our leadership to develop and discover new therapeutic antibodies that can help pets live longer, healthier lives. Collaborating with PetMedix complements our own research and development activities, and we are pleased to be working with them to explore areas of unmet clinical needs in pets."

Image (C) PetMedix.

Become a member or log in to add this story to your CPD history

Cold-water dip to raise funds for Vetlife

News Story 1
 The veterinary mental health charity Vetlife is inviting the veterinary community to join it for a sponsored cold-water dip.

The event will take place at Walpole Bay, Margate, on 17 May during Mental Health Awareness Week. Participants of all abilities can join in the challenge and are advised to bring a towel, a hot drink, a snack, and warm clothes to get changed into afterwards.

Those taking part are being asked to try to raise £100 each to support the work of the charity.

Details about how to take part can be found here. 

Click here for more...
News Shorts
Bluetongue low vector period ends

In an update to its bluetongue guidance, the Department for Environment, Food and Rural Affairs (Defra) has announced that the seasonal low vector period for the disease has ended.

With winter over, Defra is planning for a possible increase in cases as midges become more active. It has warned that farms along the east coast of England from Norfolk to Kent, and along the south coast from Kent to Devon, are at highest risk from infected midges blown over from northern Europe.

Since the virus was detected in England in November 2023, there have been 126 confirmed cases. The most recent case to be confirmed was on 1 March 2024.

Farmers are asked to continue to frequently monitor their livestock and ensure their animals and land are registered with the Animal and Plant Health Agency.